Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06239194 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Endometrial Cancer
Esophageal Cancer
Gastric Cancer
GastroEsophageal Cancer
Head and Neck Cancer
Hepatocellular Cancer
Non-small Cell Lung Cancer
Pancreatic Cancer
Prostate Cancer
Rectal Cancer
Renal Cancer
Thyroid Cancer

Interventions

DRUG: MDX2001

Sponsor

ModeX Therapeutics, An OPKO Health Company